A phase i and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8288-8294

  Plummer, Ruth ^a   Woll, Penella ^c   Fyfe, David ^c   Boddy, Alan V ^b   Griffin, Melanie ^b   Hewitt, Paula ^d   Carmichael, James ^c   Namouni, Fouad ^d   Cohen, Marvin ^d   Verrill, Mark ^a  

^a Northern Centre for Cancer Treatment   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CARBOPLATIN; CIMETIDINE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; IXABEPILONE; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PARACETAMOL; RANITIDINE; TAMOXIFEN; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOID; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INFECTION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE CANCER; MYALGIA; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NEUTROPENIA; PERIPHERAL NERVE TUMOR; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLASMA HALF LIFE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SARCOMA; SENSORY NEUROPATHY; SOLID TUMOR; SPINDLE CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; EPOTHILONES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 58149355287     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0471     Document Type: Article

References (36)

1. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992;44 Suppl 4: 1-16;discussion 66-9.
2. Rowinsky E. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-97.
3. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumors: a systematic review of clinical data. Lancet Oncol 2005;6: 229-39.
4. Patel AR, Sandler HM, Pienta KJ. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin Genitourin Cancer 2005;4:212-4.
5. Crown J, O'Leary M, OoiWS. Docetaxel and paclitaxel in the treatment of breast cancer: a reviewof clinical experience. Oncologist 2004;9:24-32.
6. Muggia F, Lu MJ. Emerging treatments for ovarian cancer. Expert Opin Emerg Drugs 2003;8:203-16.
7. Wakelee H, Belani CBDCA. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005;10:1 -10.
8. Chabner BA, Horwitz SB, Clendennin NJ, Purvis JD. Vinca alkaloids. Cancer Chemother Biol Response Modif 1991;12:67-73.
9. Gottesman M, Pastan I, Ambudkar S. P-glycoprotein and multidrug resistance. Curr Opin Gen Dev 1996;6: 610-7.
10. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999;12:565-71.
11. Hofle G, Bedorf N, Steinmetz H, Schomburg D, Gerth K, Reichenbach H. Epothilone A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. AngewChem Int Ed Engl 1996;35:1567-9.
12. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a newclass of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 1995;55: 2325-33.
13. Lee FY, Borzilleri R, Fairchild CR, et al. BMS- 247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
14. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98.
15. Gadgeel SM, WozniakA, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothi- lone B, using accelerated titration 2B design. Clin Cancer Res 2005;11:6233-9.
16. Aghajanian C, Burris HA, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.J Clin Oncol2007;25: 1082-8.
17. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21: 1866-73.
18. Pentheroudakis G, Razis E, AthanassiadisA,Pavlidis N, Fountzilas G. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol 2006;23:147-60.
19. Calvert H, Newell D, Gumbrell LA, et al. Carbo- platin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7: 1748-56.
20. Ghazal-Aswad S, Calvert H, Newell D. A single- sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 1996;37: 429-34.
21. Awada A, Jones S, Piccart M, et al. Final results of the Phase I study of the novel epothilone BMS- 247550 administered weekly in patients (pts) with advanced solid tumors [abstract 122]. Eur J Cancer 2002;38:S41.
22. de Bono JS, Hao D, Hammond LA, et al. Phase I and pharmacokinetic (PK) study of the epothilone-B analogue BMS-247550 by a continuous weekly schedule. Br J Cancer 2002;86:S110-1.
23. Zhuang SH, Agrawal M, Edgerly M, et al. A Phase I clinical trial of ixabepilone (BMS-247550), an epothi- lone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-8.
24. Eng C, Kindler HL, Nattam S, et al. A Phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 2004;15:928-32.
25. LowJ A, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic andlocallyadvanced breast cancer. J Clin Oncol 2005;23:2726-34.
26. Vansteenkiste.F, Lara PN, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small cell lung cancer whose tumors have failed first line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-55.
27. Ajani JA, Shah MA, Bokemeyer C, et al. Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane [abstract 619]. Proc Am Soc Clin Oncol 2002;21.
28. Okuno SH, Geyer SM, Maples WJ, et al. Phase 2 study of epothilone B analog (BMS-247550) in soft tissue sarcoma: an interim report [abstract 1645]. Proc Am Soc Clin Oncol 2002;21.
29. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
30. Singh DA, Kindler HL, Eng C, et al. Phase II trial of theepothilone B analog BMS-247550 in patientswith hepatobiliary cancer [abstract 1127]. Proc Am Soc Clin Oncol 2003;22.
31. Thomas E,Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25: 3399-406.
32. Galsky, MD, Small EJ, Oh WK, et al. Multi-institutional randomized Phase II trial of theepothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46.
33. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a Phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline [abstract 10511]. J Clin Oncol 2006;24:18s.
34. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
35. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via1-hour(h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized forT in HER2 normal MBC [abstract 512]. J Clin Oncol 2004;22:14S.
36. Verrill MW, Lee J, Cameron DA, et al. Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC) [abstract LBA1005]. J Clin Oncol 2007;25:18S.